Form 4 for PVLA PALVELLA THERAPEUTICS, INC.
Accepted 2024-10-28 00:00:00 ET · period of report 2024-08-07 · accession 0001437749-24-032319 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-28 | 2024-08-07 | PVLA | GERAGHTY JAMES A | Dir | P - Purchase | $1.00 | +1 | 1 | New | +$1 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Series F Preferred Stock, par value $0.001 per share | 2024-08-07 | P | A | 1 | $1.00 | 1 | D | — | — | (F1) On August 7, 2024, the Reporting Person purchased one (1) share of Series F Preferred Stock, par value $0.001 per share (the "Preferred Stock"), of Pieris Pharmaceuticals, Inc. (the "Issuer") from the Issuer for cash consideration of $1.00. The Preferred Stock has the rights, preferences, privileges and restrictions set forth in the Certificate of Designation of Series F Preferred Stock filed by the Issuer with the Nevada Secretary of State on August 7, 2024 (the "Series F COD"), including the right to have 25,000,000 votes and to vote together with the outstanding shares of the Issuer's common stock as a single class exclusively with respect to such voting proposals defined in the Series F COD. |